Metabolic profile of first and second generation antipsychotics among Chinese patients

The metabolic profiles of Chinese patients treated with second-generation antipsychotic (SGA) medication and first-generation antipsychotic (FGA) medication were compared. The sample comprised 99 patients treated with SGA (risperidone, olanzapine and ziprasidone) and 99 with FGA (chlorpromazine, hal...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry research Vol. 185; no. 3; pp. 456 - 458
Main Authors Lee, Edwin, Chow, Lai-Yin, Leung, Chi-Ming
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ireland Ltd 28.02.2011
Elsevier
Subjects
Online AccessGet full text
ISSN0165-1781
1872-7123
DOI10.1016/j.psychres.2010.04.050

Cover

More Information
Summary:The metabolic profiles of Chinese patients treated with second-generation antipsychotic (SGA) medication and first-generation antipsychotic (FGA) medication were compared. The sample comprised 99 patients treated with SGA (risperidone, olanzapine and ziprasidone) and 99 with FGA (chlorpromazine, haloperidol and trifluoperazine) from the outpatient clinic of a teaching hospital in Hong Kong. The most frequent psychiatric diagnosis was schizophrenia, followed by affective disorder and other psychiatric diagnoses. Subjects were measured for body weight, body height, fasting lipid and glucose levels. SGA was associated with higher LDL-cholesterol level than FGA. Individual comparison of different antipsychotics showed that patients on olanzapine had the greatest increases in cholesterol and triglycerides among all antipsychotics. The finding suggested SGA, particularly olanzapine, were associated with more metabolic risk factors than first-generation antipsychotics.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-1781
1872-7123
DOI:10.1016/j.psychres.2010.04.050